Minerva Neurosciences, Inc. (NERV) stock
NERVNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.18+0.02 (+0.93%)
Close on Nov 18, 2026Market cap $104.09MP/E –Yield –
Minerva Neurosciences operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Minerva Neurosciences's operating income for the twelve months ending Jun 30, 2026 was -$35.14M. For fiscal 2025 it was -$15.10M. The highest annual figure on record is $1.85M in fiscal 2020.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$15.10M | – |
| FY2024 | Dec 31, 2024 | -$21.85M | – |
| FY2023 | Dec 31, 2023 | -$23.12M | – |
| FY2022 | Dec 31, 2022 | -$25.23M | – |
| FY2021 | Dec 31, 2021 | -$45.37M | -2556.5% |
| FY2020 | Dec 31, 2020 | $1.85M | – |
| FY2019 | Dec 31, 2019 | -$75.87M | – |
| FY2018 | Dec 31, 2018 | -$51.73M | – |
| FY2017 | Dec 31, 2017 | -$41.17M | – |
| FY2016 | Dec 31, 2016 | -$30.19M | – |
| FY2015 | Dec 31, 2015 | -$26.11M | – |
| FY2014 | Dec 31, 2014 | -$54.87M | – |
| FY2013 | Dec 31, 2013 | -$3.17M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$10.64M | – |
| Q1 FY2026 | Mar 31, 2026 | -$16.67M | – |
| Q4 FY2025 | Dec 31, 2025 | -$4.98M | – |
| Q3 FY2025 | Sep 30, 2025 | -$2.84M | – |
| Q2 FY2025 | Jun 30, 2025 | -$3.37M | – |
| Q1 FY2025 | Mar 31, 2025 | -$3.90M | – |
| Q4 FY2024 | Dec 31, 2024 | -$4.52M | – |
| Q3 FY2024 | Sep 30, 2024 | -$4.37M | – |
| Q2 FY2024 | Jun 30, 2024 | -$6.28M | – |
| Q1 FY2024 | Mar 31, 2024 | -$6.68M | – |
| Q4 FY2023 | Dec 31, 2023 | -$7.17M | – |
| Q3 FY2023 | Sep 30, 2023 | -$6.08M | – |
| Q2 FY2023 | Jun 30, 2023 | -$4.52M | – |
| Q1 FY2023 | Mar 31, 2023 | -$5.35M | – |
| Q4 FY2022 | Dec 31, 2022 | -$5.07M | – |
| Q3 FY2022 | Sep 30, 2022 | -$5.21M | – |
| Q2 FY2022 | Jun 30, 2022 | -$6.97M | – |
| Q1 FY2022 | Mar 31, 2022 | -$7.99M | – |
| Q4 FY2021 | Dec 31, 2021 | -$21.38M | – |
| Q3 FY2021 | Sep 30, 2021 | -$7.52M | – |
| Q2 FY2021 | Jun 30, 2021 | -$8.96M | -130.4% |
| Q1 FY2021 | Mar 31, 2021 | -$7.51M | – |
| Q4 FY2020 | Dec 31, 2020 | -$7.30M | – |
| Q3 FY2020 | Sep 30, 2020 | -$8.09M | – |
| Q2 FY2020 | Jun 30, 2020 | $29.51M | – |
| Q1 FY2020 | Mar 31, 2020 | -$12.27M | – |
| Q4 FY2019 | Dec 31, 2019 | -$32.37M | – |
| Q3 FY2019 | Sep 30, 2019 | -$14.28M | – |
| Q2 FY2019 | Jun 30, 2019 | -$12.90M | – |
| Q1 FY2019 | Mar 31, 2019 | -$16.31M | – |
| Q4 FY2018 | Dec 31, 2018 | -$13.63M | – |
| Q3 FY2018 | Sep 30, 2018 | -$12.42M | – |
| Q2 FY2018 | Jun 30, 2018 | -$12.94M | – |
| Q1 FY2018 | Mar 31, 2018 | -$12.74M | – |
| Q4 FY2017 | Dec 31, 2017 | -$9.53M | – |
| Q3 FY2017 | Sep 30, 2017 | -$11.41M | – |
| Q2 FY2017 | Jun 30, 2017 | -$9.75M | – |
| Q1 FY2017 | Mar 31, 2017 | -$10.49M | – |
| Q4 FY2016 | Dec 31, 2016 | -$9.24M | – |
| Q3 FY2016 | Sep 30, 2016 | -$8.23M | – |
See a number that looks wrong?